Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 243 clinical trials
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy

This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and

parkinson's disease
dyskinesia
levodopa
movement disorder
  • 0 views
  • 22 Mar, 2022
  • 39 locations
Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy

This open-label study is designed to assess the long-term safety and tolerability of dipraglurant in PD patients for up to 52 weeks (at doses of 150-300 mg per day) for patients that have completed an Addex sponsored double-blind clinical trial of dipraglurant.

parkinson's disease
levodopa
  • 0 views
  • 13 May, 2022
  • 7 locations
Neurophysiological, Behavioral, and Cognitive Networks in Movement Disorders

The purpose of this study is to investigate the brain activity associated with motor and non-motor symptoms of movement disorders, including Parkinson's disease (PD) and essential tremor. These movement disorders commonly have significant non-motor features, such as depression, cognitive and memory impairment, decreased attention, speech and language disturbances, and slower …

parkinson's disease
deep brain stimulation
essential tremor
depression
tremor
  • 1 views
  • 19 Apr, 2022
  • 1 location
Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy

The primary objective of this study is to evaluate the efficacy of valbenazine versus placebo in participants aged 6 to 70 years for the treatment of dyskinesia due to cerebral palsy (DCP

  • 0 views
  • 24 Mar, 2022
  • 1 location
Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients With Levodopa Induced Dyskinesia

The aim of the study is to determine potential anti-dyskinetic properties of CPL500036 (PDE10A inhibitor) in Parkinson disease patients suffering from levodopa Induced dyskinesia. The study is

dyskinesia
levodopa
  • 0 views
  • 10 Apr, 2022
  • 3 locations
Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype

The purpose of this study is to measure mucociliary clearance (MCC) in groups of subjects with the disease Primary Ciliary Dyskinesia (PCD) caused by mutations in different genes. Some of these

  • 0 views
  • 24 Mar, 2022
  • 1 location
Influence of an Anterior Latarjet-type Abutment Operation on Scapular Dyskinesia and the Muscular Stabilization Mechanisms of the Scapula (DyScapLat)

surgery does not lead to scapular dyskinesia and modification of muscle activity compared to a control group that has not undergone an operation.

Accepts healthy volunteers
  • 0 views
  • 29 Nov, 2021
  • 1 location
Neurobiology of Functional Movement Disorder and Non-Epileptic Seizures

This study is part of a series of studies that will explore how the mind and the brain work to cause episodes of uncontrollable shaking in people who have no known underlying brain or medical disorder. The study is conducted at NIH and at the Brown University Rhode Island Hospital. …

Accepts healthy volunteers
fahn
functional movement disorder
MRI
seizure
  • 26 views
  • 18 May, 2022
  • 1 location
STEPWISE Parkinson: A Smartphone Based Exercise Solution for Patients With Parkinson's Disease (STEPWISE)

The aim of this study is to investigate whether a smartphone app can increase physical activity in patients with Parkinson's Disease in daily life for a long period of time (12 months).

  • 0 views
  • 25 Jan, 2022
  • 1 location
Effects of Music Beat on Motor Function in Individuals at Risk for Psychotic Onset and Schizophrenia Patients

dyskinesia in at-risk individuals and schizophrenia patients. It is hypothesized that the program is effective in reducing the severity of bradykinesia and dyskinesia in at-risk individuals and schizophrenia

psychiatric diseases
cognitive deficits
schizophrenia
psychotic
  • 0 views
  • 19 Aug, 2021
  • 1 location